OBJECTIVE: To determine if intermittent, low-dose, short-acting gonadotropin-releasing hormone agonist (GnRH-agonist) administration sufficiently up-regulates pituitary-gonadal function in gonadotropin deficiency to be of diagnostic or therapeutic value. DESIGN: Case-control study. SETTING: General clinical research center. PATIENT(S): Normal adult volunteers and gonadotropin-deficiency patients. INTERVENTION(S): Low-dose leuprolide acetate administered subcutaneously at 4- to 5-day intervals up to 1 year. MAIN OUTCOME MEASURE(S): Levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and sex steroid responses. RESULT(S): In normal men and women, low-dose GnRH-agonist repetitively transiently stimulated gonadotropins in a gender-dimorphic manner. In congenitally gonadotropin-deficient men (n = 6) and women (n = 1), none of whom had a normal LH response to an initial GnRH-agonist test dose, this regimen consistently stimulated LH to the normal baseline range within 2 weeks. Long-term GnRH-agonist administration to a partially gonadotropin-deficient man did not alleviate hypogonadism, however. Women with hypothalamic amenorrhea (n = 2) responded normally to a single GnRH-agonist injection; however, repeated dosing did not seem to induce the normal priming effect. CONCLUSION(S): The subnormal LH response to GnRH-agonist in patients with congenital gonadotropin deficiency normalized in response to repetitive intermittent GnRH-agonist administration but not sufficiently to improve hypogonadism. Hypothalamic amenorrhea patients lacked the priming response to repeated GnRH-agonist but otherwise had normal hormonal responses to GnRH-agonist. We conclude that intermittent administration of a short-acting GnRH-agonist is of potential diagnostic value in distinguishing hypothalamic from pituitary causes of gonadotropin deficiency.
RCT Entities:
OBJECTIVE: To determine if intermittent, low-dose, short-acting gonadotropin-releasing hormone agonist (GnRH-agonist) administration sufficiently up-regulates pituitary-gonadal function in gonadotropin deficiency to be of diagnostic or therapeutic value. DESIGN: Case-control study. SETTING: General clinical research center. PATIENT(S): Normal adult volunteers and gonadotropin-deficiencypatients. INTERVENTION(S): Low-dose leuprolide acetate administered subcutaneously at 4- to 5-day intervals up to 1 year. MAIN OUTCOME MEASURE(S): Levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and sex steroid responses. RESULT(S): In normal men and women, low-dose GnRH-agonist repetitively transiently stimulated gonadotropins in a gender-dimorphic manner. In congenitally gonadotropin-deficient men (n = 6) and women (n = 1), none of whom had a normal LH response to an initial GnRH-agonist test dose, this regimen consistently stimulated LH to the normal baseline range within 2 weeks. Long-term GnRH-agonist administration to a partially gonadotropin-deficient man did not alleviate hypogonadism, however. Women with hypothalamic amenorrhea (n = 2) responded normally to a single GnRH-agonist injection; however, repeated dosing did not seem to induce the normal priming effect. CONCLUSION(S): The subnormal LH response to GnRH-agonist in patients with congenital gonadotropin deficiency normalized in response to repetitive intermittent GnRH-agonist administration but not sufficiently to improve hypogonadism. Hypothalamic amenorrheapatients lacked the priming response to repeated GnRH-agonist but otherwise had normal hormonal responses to GnRH-agonist. We conclude that intermittent administration of a short-acting GnRH-agonist is of potential diagnostic value in distinguishing hypothalamic from pituitary causes of gonadotropin deficiency.
Authors: Balasubramanian Bhagavath; Ning Xu; Metin Ozata; Robert L Rosenfield; David P Bick; Richard J Sherins; Lawrence C Layman Journal: Mol Hum Reprod Date: 2007-01-09 Impact factor: 4.025
Authors: J S Finkelstein; R W Whitcomb; L S O'Dea; C Longcope; D A Schoenfeld; W F Crowley Journal: J Clin Endocrinol Metab Date: 1991-09 Impact factor: 5.958
Authors: Nelly Pitteloud; Andrew A Dwyer; Suzzunne DeCruz; Hang Lee; Paul A Boepple; William F Crowley; Frances J Hayes Journal: J Clin Endocrinol Metab Date: 2007-12-11 Impact factor: 5.958
Authors: D A Ehrmann; R L Rosenfield; L Cuttler; S Burstein; J F Cara; L L Levitsky Journal: J Clin Endocrinol Metab Date: 1989-11 Impact factor: 5.958
Authors: Siri Atma W Greeley; Elizabeth Littlejohn; Aliya N Husain; Darrel Waggoner; Mohan Gundeti; Robert L Rosenfield Journal: Horm Res Paediatr Date: 2017-03-02 Impact factor: 2.852
Authors: Paolo Facondo; Virginia Maltese; Andrea Delbarba; Ilenia Pirola; Mario Rotondi; Alberto Ferlin; Carlo Cappelli Journal: Front Endocrinol (Lausanne) Date: 2022-06-10 Impact factor: 6.055